From Repeated-Dose Toxicity to Carcinogenicity: Long-Term Safety Assessment Using OECD Test Guidelines 407, 408, 452, and 453
Understanding the acute effects of chemicals is an important first step; however, in real-world scenarios, humans and the environment are typically exposed to substances not just once, but over long periods and through repeated doses. Therefore, to comprehensively establish a substance’s safety profile, it is essential to systematically investigate repeated-dose toxicity, chronic effects, and carcinogenic potential. Our laboratory conducts studies in accordance with the four key OECD guidelines in this field: TG 407 (28 days), TG 408 (90 days), TG 452 (chronic toxicity), and TG 453 (combined chronic toxicity/carcinogenicity)—which are the four core OECD guidelines in this field—
OECD TG 407: 28-Day Repeated-Dose Oral Toxicity – First Step
OECD TG 407 is a basic screening test used to investigate the systemic toxic effects that a chemical may cause at repeated doses. In this study, the test substance is administered to test animals daily for 28 days via the oral route (gavage, mixed into the diet, or added to drinking water). At least three dose levels and a control group are used. Observation parameters include clinical signs, body weight, feed and water consumption, hematological and clinical biochemistry analyses, organ weights, and detailed histopathological examinations. TG 407 is used specifically to identify the chemical’s target organs, understand the dose-response relationship, and select an appropriate dose range for longer-term studies (TG 408). Under the EU REACH regulation, this test is frequently required for substances produced in quantities exceeding 10 metric tons per year.
OECD TG 408: 90-Day Subchronic Oral Toxicity – In-Depth Study
OECD TG 408 is the gold standard test for evaluating subchronic toxicity, featuring a longer exposure period and more comprehensive study parameters compared to TG 407. The 90-day study period allows for the emergence of the substance’s cumulative effects, adaptation mechanisms, and delayed toxic responses. In this study, parameters such as hematology, clinical biochemistry, and urinalysis are examined across a broader panel; histopathological evaluation covers more organs than in TG 407.
One of the most critical outcomes of TG 408 is the determination of the NOAEL (No Observed Adverse Effect Level), i.e., the highest dose level at which no observable adverse effects are observed. This value is used directly in the calculation of safe exposure limits for humans (ADI, TDI, OEL).
OECD TG 452: Chronic Toxicity Studies – Lifetime Safety
OECD TG 452 is a chronic toxicity test that models a chemical’s lifetime exposure scenario. Typically conducted in rodents over a 12-month period, this study identifies chronic degenerative effects, target organ damage, and toxic responses that may emerge with age resulting from long-term, low-dose exposure. TG 452 is a data package frequently required by regulatory authorities, particularly for food additives, pesticide residues, active pharmaceutical ingredients, and high-volume industrial chemicals. The results of this test enable the determination of the chronic NOAEL and the calculation of the long-term safety margin in human health risk assessments.
OECD TG 453: Combined Chronic Toxicity and Carcinogenicity – Final Assessment
OECD TG 453 is the most comprehensive and integrated study that combines the assessment of chronic toxicity and carcinogenicity under a single protocol. This test simultaneously evaluates both chronic toxic effects (over a 12-month period) and lifetime carcinogenic potential (typically 18–24 months) in the same test groups. Thanks to the design of TG 453, a direct relationship can be established between chronic toxicity and carcinogenicity data; for example, whether chronic hyperplasia observed in an organ progresses to neoplastic transformation can be monitored within the same population. This integrated approach significantly reduces both animal use and costs compared to conducting separate chronic toxicity and carcinogenicity studies. TG 453 is the gold standard for regulatory submissions, particularly for pesticide active ingredients, biocidal products, and industrial chemicals posing a high exposure risk.
The table below provides a comparative overview of the key features of these four OECD guidelines:
| Feature | OECD TG 407 | OECD TG 408 | OECD TG 452 | OECD TG 453 |
|---|---|---|---|---|
| Study Type | Repeated dose (subacute) | Repeated dose (subchronic) | Chronic toxicity | Combined chronic toxicity and carcinogenicity |
| Duration of Administration | 28 days | 90 days | 12 months | 12 months (chronic) + 18–24 months (carcinogenicity) |
| Route of Administration | Oral (gavage, diet, drinking water) | Oral (gastric tube, diet, drinking water) | Oral (preferably via diet or drinking water) | Oral (preferably via diet or drinking water) |
| Dose Groups | At least 3 doses + control | At least 3 doses + control | At least 3 doses + control | At least 3 doses + control (separate satellite groups for chronic and carcinogenicity) |
| Key Output | Target organ identification, preliminary LOAEL/NOAEL estimation | NOAEL, subchronic target organ profile | Chronic NOAEL, long-term organ damage | Chronic NOAEL + carcinogenic potential (tumor incidence, latency) |
| Scope of Histopathology | Selected organs (approximately 20–25 tissues) | Extended panel (approximately 35–40 tissues) | Whole-body panel (all major organs and tissues) | Whole-body panel + detailed examination of all lesions and masses |
| Number of Animals (rodents) | 40 (5 males, 5 females per group) | 80–120 (10–15 males, 10–15 females per group) | 160–240 (20–30 males, 20–30 females per group) | 400–600 (including chronic and carcinogenicity groups) |
| Regulatory Use | REACH (≥10 metric tons/year), pre-screening | REACH (≥100 metric tons/year), pesticides, biocides, pharmaceuticals | Pesticides, food additives, high-volume chemicals | Pesticide active ingredients, biocidal products, high-risk chemicals |
| Average Study Duration | Approximately 3–4 months | Approximately 5–6 months | Approximately 14–16 months | Approximately 26–30 months |
Critical Considerations in Study Design
The success of repeated-dose and chronic toxicity studies depends on a meticulous experimental design and flawless execution. In our laboratory, the following parameters are carefully evaluated before each study:
| Parameter | Description | Implementation in Our Laboratory |
|---|---|---|
| Dose Selection | The maximum tolerated dose (MTD) and environmental/human exposure levels must be taken into account. | The optimal dose range is determined through preliminary dose-finding studies and a comprehensive analysis of existing data. |
| Route of Administration and Formulation | It must be appropriate for the test substance’s physicochemical properties and the expected route of human exposure. | Dietary, drinking water, or gavage options; stability and homogeneity are validated in advance. |
| Observation and Measurement Frequency | Clinical signs should be monitored daily; body weight and feed intake weekly; and clinical pathology periodically. | A schedule programmed in accordance with GLP-compliant standard operating procedures (SOPs) is followed. |
| Histopathology Quality | It must be performed by a certified veterinary pathologist using a blinded method and standard terminology. | It is evaluated by our experienced team of pathologists working with ECVAM/INHAND-approved terminology. |
| Statistical Analysis | Dose-response relationships, trend analysis, and group comparisons must be performed using appropriate statistical methods. | Parametric/non-parametric tests appropriate for the study design and benchmark dose (BMD) modeling are applied. |
| Toxicokinetic Data Integration | Measurement of plasma/tissue concentrations is recommended to verify systemic exposure. | The toxicokinetic profile (Cmax, AUC, half-life) is determined using satellite groups. |
Study Selection Guide: Which Test, When?
The table below will guide you in selecting the appropriate test based on the product development stage and regulatory requirements:
| Development Stage / Requirement | Recommended Test | Rationale |
|---|---|---|
| Early screening, dose determination, REACH Annex VII (≥10 metric tons/year) | TG 407 (28 days) | Rapid and cost-effective target organ screening; provides a basis for dose selection in long-term studies. |
| REACH Annex IX (≥100 metric tons/year), pesticide/biocide pre-evaluation | TG 408 (90 days) | Comprehensive profile of subchronic effects; provides critical data for NOAEL determination and risk characterization. |
| REACH Annex X (≥1,000 metric tons/year), food additive authorization | TG 452 (Chronic) | Identifies the degenerative and chronic effects of long-term low-dose exposure. |
| Pesticide active ingredient registration, biocidal product approval | TG 453 (Combined Chronic/Carcinogenicity) | Provides integrated data on both chronic toxicity and carcinogenicity; it is the gold standard required by regulatory authorities. |
| Substances with genotoxic or structure-activity alerts | TG 453 | Direct assessment of carcinogenic potential is mandatory. |
| Pharmaceutical active ingredient (under ICH) | ICH S4-like + TG 452/453 | While ICH guidelines are consistent with OECD guidelines, they may include specific differences in duration and design. |
Conducting Long-Term Toxicity Studies in Our Laboratory
In our GLP-certified laboratory, we comprehensively conduct all repeated-dose toxicity tests, ranging from 28-day subacute studies to 2-year combined chronic/carcinogenicity programs. With our experienced study directors, veterinary pathologists, and quality assurance team, we guarantee scientific accuracy and regulatory compliance at every stage. In our studies, the stability and homogeneity of the test substance in the diet or drinking water are validated in advance, exposure levels are verified using toxicokinetic data, and all histopathological evaluations are performed using internationally accepted terminology (INHAND). Furthermore, in accordance with the 3R principles, we evaluate in silico and in vitro alternative methods whenever possible, and plan in vivo studies with the most optimized design.
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can one proceed directly from TG 407 to TG 452 or 453? | Although theoretically possible, selecting a dose for a chronic study without knowing the subchronic NOAEL carries a high risk. Therefore, the intermediate step of TG 408 (90 days) is generally recommended. |
| Which species are used for the TG 453 study? | Rats are the standard choice. In some cases, regulatory authorities may require a carcinogenicity study in a second species (usually mice). |
| How detailed should histopathology reports be? | For each lesion, the incidence, severity, distribution, and dose-response relationship should be reported; for neoplastic findings, the tumor type, origin, degree of invasion, and presence of metastasis should be detailed. |
| In what regulatory formats are study results presented? | The full study report can be submitted in accordance with OECD templates, in IUCLID format (for REACH), and in the specific format required by the regulatory authority (EPA, EFSA, BfR, etc.). |
| What should be done if a NOAEL cannot be determined in a study? | If an adverse effect is observed even at the lowest dose, a LOAEL (Lowest Observed Adverse Effect Level) is determined, and a risk assessment is performed using uncertainty factors. If necessary, an additional study with lower doses can be designed. |
| Is the integration of toxicokinetic data mandatory? | Although not mandatory in OECD guidelines, it is strongly recommended in modern risk assessment approaches to validate systemic exposure and for extrapolation to humans. |
Chemical safety assessment requires going beyond short-term effects to shed light on the hidden risks of long-term exposure. Our laboratory combines scientific excellence and regulatory compliance for all your repeated-dose toxicity needs, ranging from 28-day screening studies to lifetime carcinogenicity assessments. To be your trusted partner on your product’s long-term safety journey, contact us.